| P50 | author | Xiaoyuan Chen | Q67123714 |
| P2093 | author name string | Fang Li | |
| | Bing Xing | |
| | Yi Sun | |
| | Liying Cui | |
| | Feng Feng | |
| | Weihong Zhang | |
| | Yong Zeng | |
| | Renzhi Wang | |
| | Chenxi Wu | |
| | Zhaohui Zhu | |
| | Yicheng Zhu | |
| | Weihai Xu | |
| | Peiling Wu | |
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| | Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q27860791 |
| | Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study | Q33659257 |
| | Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging | Q34341677 |
| | Why integrin as a primary target for imaging and therapy | Q34912582 |
| | Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT | Q34912643 |
| | Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels | Q35062113 |
| | MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides | Q35109294 |
| | New Methods for Labeling RGD Peptides with Bromine-76. | Q35224462 |
| | Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice | Q35629161 |
| | PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. | Q35869269 |
| | Imaging key biomarkers of tumor angiogenesis | Q35999557 |
| | Evidence-based changes in devices and methods of endovascular recanalization therapy | Q36195764 |
| | Integrins and angiogenesis: a sticky business | Q36330257 |
| | First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination | Q36931413 |
| | Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers | Q37060623 |
| | Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency | Q37480688 |
| | Imaging tumor angiogenesis: the road to clinical utility | Q38123878 |
| | Postischemic revascularization: from cellular and molecular mechanisms to clinical applications | Q38153677 |
| | Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. | Q39035759 |
| | PET Imaging of Integrin αVβ3 Expression | Q42726009 |
| | Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients | Q43788666 |
| | Imaging of integrin α(V)β(3) expression using (68)Ga-RGD positron emission tomography in pediatric cerebral infarct. | Q44581741 |
| | MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides | Q45068701 |
| | Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling | Q46056304 |
| | Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction | Q46167122 |
| | Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans | Q46173308 |
| | Positron emission tomography imaging of poststroke angiogenesis | Q46299767 |
| | Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. | Q46852304 |
| | [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck | Q46897615 |
| | An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. | Q48382974 |
| | PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. | Q53083524 |
| | 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. | Q53166290 |
| | In vivo molecular imaging of angiogenesis, targeting αvβ3 integrin expression, in a patient after acute myocardial infarction | Q60607012 |
| | Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature | Q83033194 |
| | Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates | Q84700749 |
| | Elevated 99mTc 3PRGD2 activity in benign metastasizing leiomyoma | Q85924648 |
| | Combined 18F-FDG PET/CT and 99mTc 3PRGD2 SPECT/CT imaging in a case of pituitary metastases | Q86747180 |
| P433 | issue | 8 | |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 778-786 | |
| P577 | publication date | 2014-05-25 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke | |
| P478 | volume | 4 | |